

State of Oklahoma SoonerCare

Zynyz™ (Retifanlimab-dlwr) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
Drug Information		
Physician billing (HCPCS code:) Start Date (or date of next dose):		
Dose:	Dosing Regimen:	
Billing Provider Information		
Provider NPI:	Provider Name:	
Provider Phone:	Provider Fax:	
Prescriber Information		
Prescriber NPI:	Prescriber Name:_	
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria Cri		
For Initial Authorization:		
Please indicate the diagnosis and information:		
 ■ Merkel Cell Carcinoma (MCC) A. Is the diagnosis metastatic or recurrent locally advanced MCC? Yes No 		
☐ If diagnosis is not listed above, please indicate diagnosis:		
Additional Information:		
For Continued Authorization: 1. Date of last dose: 2. Does member have any evidence of progressive disease while on retifanlimab-dlwr? Yes No 3. Has the member experienced adverse drug reactions related to retifanlimab-dlwr therapy? Yes No If yes, please specify adverse reactions:		
		Date:sary and all information is true and correct to a full will result in processing delays.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 243 3/5/2024